Inovio Pharmaceuticals Stock Forecast, Price & News

Inovio Pharmaceuticals (NASDAQ:INO) Frequently Asked Questions

Is Inovio Pharmaceuticals a buy right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Inovio Pharmaceuticals in the last year. There are currently 2 sell ratings, 4 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Inovio Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in INO, but not buy additional shares or sell existing shares.
View analyst ratings for Inovio Pharmaceuticals or view top-rated stocks.

What stocks does MarketBeat like better than Inovio Pharmaceuticals?

Wall Street analysts have given Inovio Pharmaceuticals a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Inovio Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Inovio Pharmaceuticals' next earnings date?

Inovio Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, November 8th 2021.
View our earnings forecast for Inovio Pharmaceuticals.

How were Inovio Pharmaceuticals' earnings last quarter?

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) issued its quarterly earnings data on Monday, August, 9th. The biopharmaceutical company reported ($0.39) earnings per share for the quarter, missing analysts' consensus estimates of ($0.25) by $0.14. The biopharmaceutical company earned $0.27 million during the quarter, compared to analysts' expectations of $1.21 million. Inovio Pharmaceuticals had a negative trailing twelve-month return on equity of 42.42% and a negative net margin of 2,193.30%. The firm's revenue for the quarter was up 2.2% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.83) EPS.
View Inovio Pharmaceuticals' earnings history.

How has Inovio Pharmaceuticals' stock price been impacted by COVID-19?

Inovio Pharmaceuticals' stock was trading at $8.37 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, INO stock has decreased by 6.5% and is now trading at $7.83.
View which stocks have been most impacted by COVID-19.

When did Inovio Pharmaceuticals' stock split? How did Inovio Pharmaceuticals' stock split work?

Inovio Pharmaceuticals shares reverse split on the morning of Friday, June 6th 2014. The 1-4 reverse split was announced on Friday, May 23rd 2014. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, June 5th 2014. An investor that had 100 shares of Inovio Pharmaceuticals stock prior to the reverse split would have 25 shares after the split.

What price target have analysts set for INO?

9 Wall Street analysts have issued 1-year price objectives for Inovio Pharmaceuticals' stock. Their forecasts range from $6.00 to $35.00. On average, they expect Inovio Pharmaceuticals' stock price to reach $14.13 in the next year. This suggests a possible upside of 80.4% from the stock's current price.
View analysts' price targets for Inovio Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are Inovio Pharmaceuticals' key executives?

Inovio Pharmaceuticals' management team includes the following people:

• J. Joseph Kim, President, Chief Executive Officer & Director
• Jacqueline E. Shea, Chief Operating Officer & Executive Vice President
• Peter D. Kies, Chief Financial Officer
• Stephen Kemmerrer, Senior Vice President-Engineering Development
• Kate E. Broderick, Senior Vice President-Research & Development

What is J. Joseph Kim's approval rating as Inovio Pharmaceuticals' CEO?

12 employees have rated Inovio Pharmaceuticals CEO J. Joseph Kim on Glassdoor.com. J. Joseph Kim has an approval rating of 82% among Inovio Pharmaceuticals' employees.

Who are some of Inovio Pharmaceuticals' key competitors?

Some companies that are related to Inovio Pharmaceuticals include Integra LifeSciences (IART), ICU Medical (ICUI), Nevro (NVRO), Inari Medical (NARI), Merit Medical Systems (MMSI), Haemonetics (HAE), The Beauty Health (SKIN), AtriCure (ATRC), NuVasive (NUVA), Axonics (AXNX), Glaukos (GKOS), Silk Road Medical (SILK), iRhythm Technologies (IRTC), Treace Medical Concepts (TMCI) and Pulmonx (LUNG).
View all of INO's competitors.

What other stocks do shareholders of Inovio Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Inovio Pharmaceuticals investors own include Novavax (NVAX), Moderna (MRNA), Gilead Sciences (GILD), NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), Pfizer (PFE), Micron Technology (MU), Sorrento Therapeutics (SRNE) and Vaxart (VXRT).

What is Inovio Pharmaceuticals' stock symbol?

Inovio Pharmaceuticals trades on the NASDAQ under the ticker symbol "INO."

Who are Inovio Pharmaceuticals' major shareholders?

Inovio Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (8.68%), Vanguard Group Inc. (5.20%), State Street Corp (4.23%), Geode Capital Management LLC (1.72%), Wasatch Advisors Inc. (1.70%) and JPMorgan Chase & Co. (1.64%). Company insiders that own Inovio Pharmaceuticals stock include David B Weiner, David B Weiner, Jacqueline Elizabeth Shea, Jong Joseph Kim, Laurent Humeau, Lota S Zoth, Peter Kies and Simon X Benito.
View institutional ownership trends for Inovio Pharmaceuticals.

Which major investors are selling Inovio Pharmaceuticals stock?

INO stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Citadel Advisors LLC, IMC Chicago LLC, Seven Eight Capital LP, Bank of Montreal Can, Bank of America Corp DE, Aristides Capital LLC, and Creative Planning. Company insiders that have sold Inovio Pharmaceuticals company stock in the last year include David B Weiner, Jacqueline Elizabeth Shea, Jong Joseph Kim, Laurent Humeau, Lota S Zoth, Peter Kies, and Simon X Benito.
View insider buying and selling activity for Inovio Pharmaceuticals or view top insider-selling stocks.

Which major investors are buying Inovio Pharmaceuticals stock?

INO stock was acquired by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Goldman Sachs Group Inc., BlackRock Inc., State Street Corp, Morgan Stanley, Morgan Stanley, Nuveen Asset Management LLC, and Wasatch Advisors Inc..
View insider buying and selling activity for Inovio Pharmaceuticals or or view top insider-buying stocks.

How do I buy shares of Inovio Pharmaceuticals?

Shares of INO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Inovio Pharmaceuticals' stock price today?

One share of INO stock can currently be purchased for approximately $7.83.

How much money does Inovio Pharmaceuticals make?

Inovio Pharmaceuticals has a market capitalization of $1.65 billion and generates $7.41 million in revenue each year. The biopharmaceutical company earns $-166,410,000.00 in net income (profit) each year or ($0.82) on an earnings per share basis.

How many employees does Inovio Pharmaceuticals have?

Inovio Pharmaceuticals employs 262 workers across the globe.

When was Inovio Pharmaceuticals founded?

Inovio Pharmaceuticals was founded in 1979.

What is Inovio Pharmaceuticals' official website?

The official website for Inovio Pharmaceuticals is www.inovio.com.

Where are Inovio Pharmaceuticals' headquarters?

Inovio Pharmaceuticals is headquartered at 660 W. GERMANTOWN PIKE SUITE 110., PLYMOUTH MEETING PA, 19462.

How can I contact Inovio Pharmaceuticals?

Inovio Pharmaceuticals' mailing address is 660 W. GERMANTOWN PIKE SUITE 110., PLYMOUTH MEETING PA, 19462. The biopharmaceutical company can be reached via phone at (267) 440-4200 or via email at [email protected].